Swain SM, Baselga J, Kim S-B, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero J-M, Schneeweiss A, Heeson S, Clark E, Ross G, Benyunes MC, Cortés J, CLEOPATRA Study Group (2015) Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Eng J Med 372(8):724–734
von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J, APHINITY Steering Committee and Investigators (2017) Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Eng J Med 377(2):122–131
Wing M (2008) Monoclonal antibody first dose cytokine release syndromes-mechanisms and prediction. J Immunotoxical 5(1):11–15
Khoury A, Parihar V, O’steen L, Cherabuddi K (2018) Pertuzumab and trastuzumab infusion related cytokine release syndrome in a chemotherapy naive patient with metastatic breast cancer. Breast J 24(3):383–384
Schwartzberg LS, Stepanski EJ, Walker MS, Mathias S, Houts AC, Fortner BV (2009) Implications of IV monoclonal antibody infusion reaction for the patient, caregiver, and practice: results of a multicenter study. Support Care Cancer 17(1):91–98
Thompson LM, Eckmann K, Boster BL, Hess KR, Michaud LB, Esteva FJ, Hortobágyi GN, Barnett CM (2014) Incidence, risk factors, and management of infusion-related reactions in breast cancer patients receiving trastuzumab. Oncologist 19(3):228–234
Article CAS PubMed PubMed Central Google Scholar
Ring A, Simcock R, Mitra S, Bloomfield D, King J, Simpson S, Sadler G, Webb A (2008) Infusion of trastuzumab maintenance doses over 30 minutes. Ann oncol 19(8):1509–1510
Article CAS PubMed Google Scholar
Herceptin [PackageInsert]. South SanFrancisco, CA: Genentech, Inc.; October 2010. http://www.gene.com/download/pdf/herceptin_prescribing.pdf Accessed April 11, 2022.
European medicines agency: summary of product characteristics for perjeta (pertuzumab) https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf. Accessed 20 Apr 2022
Chung CH (2008) Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist 13(6):725–732
Article CAS PubMed Google Scholar
National Cancer Institute. Common Terminology Criteria for Adverse Events v5.0. (CTCAE) Publish date November 27, 2017. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50. Accessed April 11, 2022.
Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’for medical statistics. Bone Marrow Transplant 48(3):452–458
Article CAS PubMed Google Scholar
Nakamura Y, Okamoto W, Kato T, Esaki T, Kato K, Komatsu Y, Yuki S, Masuishi T, Nishina T, Ebi H, Sawada K, Taniguchi H, Fuse N, Nomura S, Fukui M, Matsuda S, Sakamoto Y, Uchigata H, Kitajima K, Kuramoto N, Asakawa T, Olsen S, Odegaard JI, Sato A, Fujii S, Ohtsu A, Yoshino T (2021) Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial. Nat Med 27(11):1899–1903
Article CAS PubMed PubMed Central Google Scholar
Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A (1999) Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 94(7):2217–2224
Article CAS PubMed Google Scholar
Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M (2009) Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 69(24):9330–9336
Article CAS PubMed Google Scholar
Wang Y-Y, Zhou Na, Liu H-S, Gong X-L, Zhu R, Li X-Y, Sun Z, Zong X-H, Li N-N, Meng C-T, Bai C-M, Li T-S (2020) Circulating activated lymphocyte subsets as potential blood biomarkers of cancer progression. Cancer Med 9(14):5086–5094
留言 (0)